Tom Woiwode, Ph.D., has been working with Versant since 2002, and has served in both operational and investment roles during that time. Tom was the start-up CBO for Amira (sale), Synosia (sale) and Flexion (2014 IPO) and was the COO of Okairos where he led the process that culminated in the acquisition by GSK. Since being promoted to Managing Director in 2014, Tom has assumed the lead role in multiple investments that also have reached liquidity including Crispr (2016 IPO), Audentes (2016 IPO), Annapurna (merged to form Adverum), Gritstone (2018 IPO), Crinetics (2018 IPO), Jecure (sale), Therachon (sale), Aligos (2020 IPO), Passage (2020 IPO), Tempest (2021 reverse merger) and Vividion (sale).
Location
San Francisco, California
Notable investments
No items found.
Check size range(s)
$0 - $100K
$100K - $500K
$500K - $1M
$1M - $3M
$3M - $10M
Rounds their fund invests in
Series A
Rounds their fund leads
No items found.
Sectors their fund invests in
Biotech
Geographies their fund invests in
USA
Canada
Europe
Browse through a massive startup database
Browse Harmonic, our favorite resource for parsing through the world's startup data.
Partner
Learn more about Harmonic
No items found.
No colleagues here yet.
Funds they're a part of
Versant Ventures
About the Fund
Provides state-of-the-art laboratories to launch novel biotech companies with academic founders.
View Profile
Their Colleagues
Sheets Their fund(s) are in
Is this you? Have any edits?
Fill out our update request form and we'll update ASAP
Related Investors
Round-focused Sheets
Geography-focused Sheets
Sector-focused Sheets
